CALCIJEX Drug Patent Profile
✉ Email this page to a colleague
When do Calcijex patents expire, and when can generic versions of Calcijex launch?
Calcijex is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in CALCIJEX is calcitriol. There are ten drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the calcitriol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Calcijex
A generic version of CALCIJEX was approved as calcitriol by TEVA on October 12th, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CALCIJEX?
- What are the global sales for CALCIJEX?
- What is Average Wholesale Price for CALCIJEX?
Summary for CALCIJEX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 90 |
| Clinical Trials: | 5 |
| Patent Applications: | 4,220 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | CALCIJEX at DailyMed |
Recent Clinical Trials for CALCIJEX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 1 |
| Roswell Park Cancer Institute | Phase 1 |
| Statistika Consultoria Ltda | Phase 4 |
US Patents and Regulatory Information for CALCIJEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | CALCIJEX | calcitriol | INJECTABLE;INJECTION | 018874-001 | Sep 25, 1986 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | CALCIJEX | calcitriol | INJECTABLE;INJECTION | 018874-002 | Sep 25, 1986 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CALCIJEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | CALCIJEX | calcitriol | INJECTABLE;INJECTION | 018874-001 | Sep 25, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | CALCIJEX | calcitriol | INJECTABLE;INJECTION | 018874-002 | Sep 25, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | CALCIJEX | calcitriol | INJECTABLE;INJECTION | 018874-001 | Sep 25, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | CALCIJEX | calcitriol | INJECTABLE;INJECTION | 018874-002 | Sep 25, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | CALCIJEX | calcitriol | INJECTABLE;INJECTION | 018874-001 | Sep 25, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | CALCIJEX | calcitriol | INJECTABLE;INJECTION | 018874-001 | Sep 25, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | CALCIJEX | calcitriol | INJECTABLE;INJECTION | 018874-002 | Sep 25, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CALCIJEX
See the table below for patents covering CALCIJEX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 2209352 | ⤷ Sign Up | |
| Canada | 1174605 | PREPARATION AQUEUSE, DILUEE ET STABILISEE, A BASE DE 1.alpha., 25-DIHYDROXYCHOLECALCIFEROL POUR ADMINISTRATION NEONATALE (STABILIZED, DILUTE AQUEOUS PREPARATION OF 1.alpha., 25- DIHYDROXYCHOLECALCIFEROL FOR NEONATAL ADMINISTRATION) | ⤷ Sign Up |
| Japan | S5544727 | ⤷ Sign Up | |
| Israel | 64798 | ⤷ Sign Up | |
| United Kingdom | 1331011 | ⤷ Sign Up | |
| Canada | 962666 | 1,25-DIHYDROXYCHOLECALIFEROL | ⤷ Sign Up |
| Japan | S6144845 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
